Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

Lopez-Ruz MA, Navas P, López-Zúñiga MA, Gonzalvo MC, Sampedro A, Pasquau J, Hidalgo-Tenorio C, Javier R, Castilla JA.

PLoS One. 2016 Jul 21;11(7):e0159305. doi: 10.1371/journal.pone.0159305. eCollection 2016.

2.

Nuke-Sparing Regimens for the Long-Term Care of HIV Infection.

Pasquau J, Hidalgo-Tenorio C.

AIDS Rev. 2015 Oct-Dec;17(4):220-30.

3.

[Duration of antimicrobial therapy].

Pasquau J, Matesanz M.

Rev Esp Quimioter. 2015 Sep;28 Suppl 1:30-3. Review. Spanish.

4.

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.

Pedrol E, Llibre JM, Tasias M, Currán A, Guardiola JM, Deig E, Guelar A, Martínez-Madrid O, Tikhomirova L, Ramírez R; RELAX Study Group.

HIV Med. 2015 Nov;16(10):628-34. doi: 10.1111/hiv.12298. Epub 2015 Aug 4.

PMID:
26238151
5.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Sep;15(9):998.

PMID:
26062881
6.

The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.

Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, Crespo M, Bravo I, Pasquau J, Garcia Del Toro M, Herrero C, Rivero A, Moreno S, Llibre JM.

AIDS Res Hum Retroviruses. 2015 Sep;31(9):893-7. doi: 10.1089/AID.2015.0016. Epub 2015 Jun 15.

PMID:
26059859
7.

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S.

Antiviral Res. 2015 Aug;120:79-84. doi: 10.1016/j.antiviral.2015.05.001. Epub 2015 May 12.

PMID:
25977241
8.

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.

Shaw E, Miró JM, Puig-Asensio M, Pigrau C, Barcenilla F, Murillas J, Garcia-Pardo G, Espejo E, Padilla B, Garcia-Reyne A, Pasquau J, Rodriguez-Baño J, López-Contreras J, Montero M, de la Calle C, Pintado V, Calbo E, Gasch O, Montejo M, Salavert M, Garcia-Pais MJ, Carratalà J, Pujol M; Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); Instituto de Salud Carlos III, Madrid, Spain; GEIH (Hospital Infection Study Group).

BMJ Open. 2015 Mar 11;5(3):e006723. doi: 10.1136/bmjopen-2014-006723.

9.

[Study of human immunodeficiency virus transmission chains in Andalusia: analysis from baseline antiretroviral resistance sequences].

Pérez-Parra S, Chueca-Porcuna N, Álvarez-Estevez M, Pasquau J, Omar M, Collado A, Vinuesa D, Lozano AB, García-García F.

Enferm Infecc Microbiol Clin. 2015 Nov;33(9):603-8. doi: 10.1016/j.eimc.2014.11.016. Epub 2015 Feb 1. Spanish.

PMID:
25648468
10.

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.

Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19814. doi: 10.7448/IAS.17.4.19814. eCollection 2014.

11.

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.

Pasquau J, López-Cortés L, Mayorga MI, Viciana P, Del Mar Arenas M, Ríos MJ, Hernández-Quero J, Castaño M, Merino MD, Márquez M, Vergara A, Terrón A, Téllez F, Hidalgo-Tenorio C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19813. doi: 10.7448/IAS.17.4.19813. eCollection 2014.

12.

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.

Valero IP, Pasquau J, Rubio R, Ribero A, Santos J, Sanz J, Mariño A, Crespo M, Hernandez J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Pérez-Molina JA.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19656. doi: 10.7448/IAS.17.4.19656. eCollection 2014.

13.

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.

Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19520. doi: 10.7448/IAS.17.4.19520. eCollection 2014.

14.

[Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study].

Pedrol E, Viciana P, Arranz A, Pasquau J, Deig E, Tasias M; SWITH AUDIT study group.

Rev Esp Quimioter. 2014 Jun;27(2):93-7. Spanish.

15.

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

Macías J, Recio E, Márquez M, García C, Jiménez P, Merino D, Muñoz L, Pasquau J, Ojeda G, Bancalero P, Chueca N, Pineda JA.

HIV Med. 2014 Aug;15(7):417-24. doi: 10.1111/hiv.12129. Epub 2014 Feb 24.

16.

Assisted reproductive technology and obstetric outcome in couples when the male partner has a chronic viral disease.

Molina I, Carmen Del Gonzalvo M, Clavero A, Angel López-Ruz M, Mozas J, Pasquau J, Sampedro A, Martínez L, Castilla JA.

Int J Fertil Steril. 2014 Jan;7(4):291-300. Epub 2013 Dec 22.

17.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.

18.

A review of the factors influencing antimicrobial prescribing.

Calbo E, Alvarez-Rocha L, Gudiol F, Pasquau J.

Enferm Infecc Microbiol Clin. 2013 Sep;31 Suppl 4:12-5. doi: 10.1016/S0213-005X(13)70127-7.

PMID:
24129284
19.

Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.

López-Cortés LE, Del Toro MD, Gálvez-Acebal J, Bereciartua-Bastarrica E, Fariñas MC, Sanz-Franco M, Natera C, Corzo JE, Lomas JM, Pasquau J, Del Arco A, Martínez MP, Romero A, Muniain MA, de Cueto M, Pascual A, Rodríguez-Baño J; REIPI/SAB group.

Clin Infect Dis. 2013 Nov;57(9):1225-33. doi: 10.1093/cid/cit499. Epub 2013 Aug 8. Review.

20.

[Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus].

Mensa J, Soriano A, Llinares P, Barberán J, Montejo M, Salavert M, Alvarez-Rocha L, Maseda E, Moreno A, Pasquau J, Gómez J, Parra J, Candel J, Azanza JR, García JE, Marco F, Soy D, Grau S, Arias J, Fortún J, de Alarcón CA, Picazo J; Sociedad Española de Quimioterapia (SEQ); Sociedad Española de Medicina Interna (SEMI); GTIPO-Sociedad Española de Anestesiología y Reanimación.

Rev Esp Quimioter. 2013 Jan;26 Suppl 1:1-84. Review. Spanish. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk